Note 2. Acquisitions The Company makes acquisitions to enhance its capabilities and offerings in certain areas, including technology services. During the three months ended March 31, 2015, the Company completed one non-U.S. acquisition of a business that performs sourcing and commercial reporting of drug utilization data for the pharmaceutical industry. The business combination was accounted for under the acquisition method of accounting, and as such, the aggregate purchase price was allocated on a preliminary basis to the assets acquired and liabilities assumed based on estimated fair values as of the closing date. The purchase price allocation will be finalized after the completion of the valuation of certain intangible assets and any adjustments to the preliminary purchase price allocation are not expected to have a material impact on the Company s results of operations. The Condensed Consolidated Financial Statements include the results of the acquisition subsequent to its closing. Had the acquisition occurred as of the beginning of 2014, the impact on the Company s results of operations would not have been material. Summary Financial Information Financial information related to the acquisition is as follows: Weighted-Average March 31, (in millions) Amortization Period 2015 Total cost of acquisition $ 27 Amounts recorded in the Condensed Consolidated Statements of Financial Position: Goodwill $ 11 Portion of goodwill deductible for tax purposes   Intangible assets: Client relationships 10 years $ 18 Covenant not to compete 3 years 2 Databases 1 year 1 Trade names 3 years 1 Total intangible assets $ 22 Contingent consideration Under the terms of certain acquisition-related purchase agreements, the Company may be required to pay additional amounts as contingent consideration based on the achievement of certain financial performance related metrics, ranging from $0 to $21 million through 2017. The Company s contingent consideration recorded on the balance sheet was approximately $21 million and $24 million at Ma